Valbiotis (XPAR:ALVAL) Cash-to-Debt : 3.64 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Valbiotis Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Valbiotis's cash to debt ratio for the quarter that ended in Dec. 2023 was 3.64.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Valbiotis could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Valbiotis's Cash-to-Debt or its related term are showing as below:

XPAR:ALVAL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.66 Med: 2.65 Max: 6.26
Current: 3.64

During the past 9 years, Valbiotis's highest Cash to Debt Ratio was 6.26. The lowest was 0.66. And the median was 2.65.

XPAR:ALVAL's Cash-to-Debt is ranked worse than
58.22% of 1527 companies
in the Biotechnology industry
Industry Median: 6.24 vs XPAR:ALVAL: 3.64

Valbiotis Cash-to-Debt Historical Data

The historical data trend for Valbiotis's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Valbiotis Cash-to-Debt Chart

Valbiotis Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

1.68

2.08

2.87

2.90

3.64

Valbiotis Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial											2.87	2.15	2.90	2.04	3.64

Competitive Comparison of Valbiotis's Cash-to-Debt

For the Biotechnology subindustry, Valbiotis's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valbiotis's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valbiotis's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Valbiotis's Cash-to-Debt falls into.

Valbiotis Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Valbiotis's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	25.017	/	(2.107	+	4.773)
	=	3.64

Valbiotis's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	25.017	/	(2.107	+	4.773)
	=	3.64

Valbiotis (XPAR:ALVAL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Valbiotis Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Valbiotis's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Valbiotis (XPAR:ALVAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valbiotis SA (XPAR:ALVAL) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

8JD:Germany

Address

12F rue Paul VATINE, Perigny, La Rochelle, FRA, 17180

Website

http://www.valbiotis.com

Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of major metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.

Valbiotis (XPAR:ALVAL) Headlines

No Headlines